RAIN logo

RAIN Stock

Profile

Full Name:

Rain Oncology Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

02 January 2025

Indexes:

Not included

Website:

http://www.rainoncology.com

Description:

As of January 26, 2024, operates as a subsidiary of Pathos AI, Inc.

Key Details

Price

$3.78

Market Cap

$25.93 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

-

Annual EPS

-$0.06(+97.65% YoY)

PE Ratio

-

Annual ROE

68.61%

Annual Debt To Equity

-0.96

Beta

-16.67

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Mar 08, 2024

Recent annual earnings:

Mar 08, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

18 Sept '23 Citigroup
Neutral
05 June '23 Mizuho
Neutral
02 June '23 Roth MKM
Neutral
02 June '23 HC Wainwright & Co.
Neutral
30 May '23 Roth MKM
Neutral
30 May '23 EF Hutton
Hold
23 May '23 Piper Sandler
Neutral
23 May '23 Oppenheimer
Perform
23 May '23 JonesTrading
Hold
23 May '23 HC Wainwright & Co.
Neutral

Screeners with RAIN included

Small cap stocks
NASDAQ earnings calendar
Stocks above SMA 50
Stocks with low beta
Stocks above SMA 200
Stocks recommended to hold
Companies with buyback

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$3.78
RAIN price is $3.78

Price All-time High

$20.91
RAIN price is currently -81.92% below its historical high of $20.91

Market Cap

$25.93 M
RAIN market capitalization is $25.93 million

Beta

-16.67
RAIN beta is -16.67

200-day SMA

$1.75
RAIN price is currently +116.62% above its 200-day simple moving average

14-day RSI

50.96
RAIN 14-day relative strength index is 50.96

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Net Income 3-Year Change

+97.93%
RAIN annual net profit is up +97.93% over the past 3 years

Annual EPS 3-Year Change

+96.78%
RAIN annual earnings per share is up +96.78% over the past 3 years

Annual EPS Estimate

-$0.35
RAIN annual earnings per share is currently -81.80% lower than the consensus analysts' forecast

Annual Operating Profit

-$410.10 K
RAIN annual operaing income is -$410.10 thousand

Annual Operating Profit 3-Year Change

+97.84%
RAIN annual operaing income is up +97.84% over the past 3 years

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual ROE

68.61%
RAIN annual return on equity is 68.61%

Annual ROA

-84.40%
RAIN annual return on assets is -84.40%

Annual EBIT

-$410.00 K
RAIN annual earnings before interest & taxes is -$410.00 thousand

Annual EBITDA

-$397.30 K
RAIN annual earnings before interest, taxes, depreciation & amortization is -$397.30 thousand

Annual Interest Coverage Ratio

-15.19
RAIN annual interest coverage ratio is -15.19

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PB Ratio Sector Rank

1.22%
RAIN price to book ratio is higher than 1.22% of companies in Healthcare sector

Enterprise Value

$26.50 M
RAIN enterprise value is $26.50 million

Enterprise Value 1-Year Change

-40.58%
RAIN enterprise value is down -40.58% year-on-year

EV/EBITDA

-8.72
RAIN EV/EBITDA is -8.72

EV/EBITDA Sector Rank

15.86%
RAIN EV/EBITDA is higher than 15.86% of companies in Healthcare sector

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Debt To Equity Sector Rank

7.75%
RAIN annual debt to equity ratio is higher than 7.75% of companies in Healthcare sector

Annual Current Ratio

0.04
RAIN annual current ratio is 0.04

Annual Current Ratio Sector Rank

0.72%
RAIN annual current ratio is higher than 0.72% of companies in Healthcare sector

Annual Total Assets

$517.80 K
RAIN annual total assets is $517.80 thousand

Annual Current Assets

$45.50 K
RAIN annual total current assets is $45.50 thousand

Annual Total Liabilities

$1.15 M
RAIN annual total liabilities is $1.15 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CFO 3-Year Change

+97.88%
RAIN annual cash flow from operations is up +97.88% over the past 3 years

Annual CFI 3-Year Change

+94.91%
RAIN annual cash flow from investing activities is up +94.91% over the past 3 years

Annual CFF 3-Year Change

-99.37%
RAIN annual cash flow from financing activities is down -99.37% over the past 3 years

Annual FCF

-$502.30 K
RAIN annual free cash flow is -$502.30 thousand

Annual FCF 3-Year Change

+96.94%
RAIN annual free cash flow is up +96.94% over the past 3 years

Institutional Ownership

Similar stocks

FEMY logo
Femasys (FEMY)
PULM logo
Pulmatrix (PULM)
PLUR logo
Pluri (PLUR)
BCAB logo
BioAtla (BCAB)
DARE logo
Dare Bioscience (DARE)
ITRM logo
Iterum Therapeutics (ITRM)
LVTX logo
LAVA Therapeutics NV (LVTX)
COEP logo
Coeptis Therapeutics (COEP)
VSee Health (VSEE)
Rain Oncology Inc. (RAIN) Q2 2023 Earnings Call Transcript
Rain Oncology Inc. (RAIN) Q2 2023 Earnings Call Transcript
Rain Oncology Inc. (RAIN) Q2 2023 Earnings Call Transcript
RAIN
Seeking Alpha10 August 2023

Rain Oncology Inc. (NASDAQ:RAIN ) Q2 2023 Earnings Call Transcript August 10, 2023 5:00 PM ET Company Participants Dan Ferry - IR, LifeSci Advisors Avanish Vellanki - CEO Nelson Cabatuan - Acting SVP, Finance Robert Doebele - CSO Conference Call Participants Ashiq Mubarack - Citigroup Joe Catanzaro - Piper Sandler Anshul Dhankher - LifeSci Capital Avantika Joshi - Mizuho Securities Mitchell Kapoor - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Rain Oncology Inc. Second Quarter 2023 Earnings Conference Call.

Why Is RAIN Stock Down 87% Today?
Why Is RAIN Stock Down 87% Today?
Why Is RAIN Stock Down 87% Today?
RAIN
InvestorPlace22 May 2023

Rain Oncology (NASDAQ: RAIN ) stock is taking a massive beating on Monday after the company revealed its latest clinical trial data. The bad news for investors in RAIN stock is the company's Phase 3 MANTRA trial failed to meet its primary endpoint.

Rain Oncology, Inc. (RAIN) Q1 2023 Earnings Call Transcript
Rain Oncology, Inc. (RAIN) Q1 2023 Earnings Call Transcript
Rain Oncology, Inc. (RAIN) Q1 2023 Earnings Call Transcript
RAIN
Seeking Alpha13 May 2023

Rain Oncology, Inc. (NASDAQ:RAIN ) Q1 2023 Earnings Conference Call May 11, 2023 5:00 PM ET Company Participants Dan Ferry - IR, LifeSci Advisors Avanish Vellanki - CEO Robert Doebele - CSO Richard Bryce - CMO Nelson Cabatuan - SVP, Finance Conference Call Participants Yigal Nochomovitz - Citigroup Michael Schmidt - Guggenheim Joe Catanzaro - Piper Sandler Soumit Roy - Jones Trading Sam Slutsky - LifeSci Capital Jeff Jones - Oppenheimer Faisal Khurshid - SVB Securities Mitchell Kapoor - H.C. Wainwright Avantika Joshi - Mizuho Securities Tony Butler - EF Hutton Operator Greetings, and welcome to the Rain Oncology, Inc. First Quarter 2023 Earnings Call.

Rain Oncology: Major Catalysts Ahead, With Supportive Prior Data
Rain Oncology: Major Catalysts Ahead, With Supportive Prior Data
Rain Oncology: Major Catalysts Ahead, With Supportive Prior Data
RAIN
Seeking Alpha27 April 2023

Rain Oncology: Major Catalysts Ahead, With Supportive Prior Data.

Rain Oncology: Phase 3 Milademetan Data Expected Q2 Of 2023
Rain Oncology: Phase 3 Milademetan Data Expected Q2 Of 2023
Rain Oncology: Phase 3 Milademetan Data Expected Q2 Of 2023
RAIN
Seeking Alpha26 April 2023

Rain Oncology: Phase 3 Milademetan Data Expected Q2 Of 2023.

FAQ

  • What is the primary business of Rain Enhancement Technologies Holdco?
  • What is the ticker symbol for Rain Enhancement Technologies Holdco?
  • Does Rain Enhancement Technologies Holdco pay dividends?
  • What sector is Rain Enhancement Technologies Holdco in?
  • What industry is Rain Enhancement Technologies Holdco in?
  • What country is Rain Enhancement Technologies Holdco based in?
  • When did Rain Enhancement Technologies Holdco go public?
  • Is Rain Enhancement Technologies Holdco in the S&P 500?
  • Is Rain Enhancement Technologies Holdco in the NASDAQ 100?
  • Is Rain Enhancement Technologies Holdco in the Dow Jones?
  • When was Rain Enhancement Technologies Holdco's last earnings report?
  • When does Rain Enhancement Technologies Holdco report earnings?
  • Should I buy Rain Enhancement Technologies Holdco stock now?

What is the primary business of Rain Enhancement Technologies Holdco?

As of January 26, 2024, operates as a subsidiary of Pathos AI, Inc.

What is the ticker symbol for Rain Enhancement Technologies Holdco?

The ticker symbol for Rain Enhancement Technologies Holdco is NASDAQ:RAIN

Does Rain Enhancement Technologies Holdco pay dividends?

No, Rain Enhancement Technologies Holdco does not pay dividends

What sector is Rain Enhancement Technologies Holdco in?

Rain Enhancement Technologies Holdco is in the Healthcare sector

What industry is Rain Enhancement Technologies Holdco in?

Rain Enhancement Technologies Holdco is in the Biotechnology industry

What country is Rain Enhancement Technologies Holdco based in?

Rain Enhancement Technologies Holdco is headquartered in United States

When did Rain Enhancement Technologies Holdco go public?

Rain Enhancement Technologies Holdco's initial public offering (IPO) was on 02 January 2025

Is Rain Enhancement Technologies Holdco in the S&P 500?

No, Rain Enhancement Technologies Holdco is not included in the S&P 500 index

Is Rain Enhancement Technologies Holdco in the NASDAQ 100?

No, Rain Enhancement Technologies Holdco is not included in the NASDAQ 100 index

Is Rain Enhancement Technologies Holdco in the Dow Jones?

No, Rain Enhancement Technologies Holdco is not included in the Dow Jones index

When was Rain Enhancement Technologies Holdco's last earnings report?

Rain Enhancement Technologies Holdco's most recent earnings report was on 8 March 2024

When does Rain Enhancement Technologies Holdco report earnings?

The date for Rain Enhancement Technologies Holdco's next earnings report has not been announced yet

Should I buy Rain Enhancement Technologies Holdco stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions